Manuel Hernández-Guerra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Manuel Hernández-Guerra has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Enrique Quintero
Liver Unit, Hospital Universitario de Canarias
26 shared publications - Antonio Zebenzuy Gimeno-García
Servicio de Gastroenterología, Hospital Universitario de Canarias, Tenerife, Spain
16 shared publications - Juan Carlos García-Pagán
Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
15 shared publications - Juan Turnes
Servicio de Aparato Digestivo, Complejo Hospitalario Universitario de Pontevedra, IIS Galicia Sur, Pontevedra, España
15 shared publications - Javier Crespo
Cantabria Cohort, Valdecilla Research Institute (IDIVAL), 39011 Santander, Spain
12 shared publications Jaime Bosch
Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi I i Sunyer, IMDIM, University of Barcelona, Barcelona, Spain
11 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Revisiting Ferritin‐ IgG Score to Predict Complete Biochemical Response in Autoimmune Hepatitis
Background: Predictive tools in autoimmune hepatitis (AIH) are scarce. A study proposed low ferritin and high IgG as prognostic markers for complete biochemical response (CBR). Aims: We aimed to externally validate the prognostic role of ferritin‐IgG score and its individual components in an independent multicentre AIH cohort. Methods: This multicentre study included 487 patients from the Hannover cohort ( n = 166) and the Spanish ColHai registry ( n = 321). Patients with ferritin < 2.09×ULN received 1 point and those with IgG > 1.89×ULN received 1 point, yielding a score of 0–2. Because baseline characteristics differed between cohorts, the score was additionally evaluated after inverse probability of treatment weighting (IPTW) propensity score. Results: At baseline, Hannover patients were younger ( p = 0.005) and had higher transaminases, bilirubin ( p < 0.001), ferritin ( p = 0.006) and IgG ( p = 0.006). Overall, 79.7% achieved CBR; CBR rates were higher in ColHai at 6 (50.2% vs. 34.6%, p = 0.001) and 12 months (67.6% vs. 51.9%, p = 0.001). The score was associated with response in the Hannover cohort but showed no predictive capacity in ColHai (C‐statistic 0.51 [95% CI 0.45–0.56] at 6 months; 0.51 [0.45–0.57] at 12 months; 0.54 [0.47–0.61] at any time during the follow‐up). After IPTW, the score was not associated with CBR in the ColHai cohort (HR 0.86, 95% CI 0.67–1.10), whereas IgG retained its predictive value, with baseline levels < 1.89×ULN associated with a higher probability of achieving CBR. Conclusions: The ferritin‐IgG score failed external validation in an independent multicentre cohort. Ferritin showed no prognostic value, whereas the predefined IgG threshold retained its ability to predict treatment response.
- 28 September 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Open AccessRevisiting Ferritin‐ IgG Score to Predict Complete Biochemical Response in Autoimmune Hepatitis
Background: Predictive tools in autoimmune hepatitis (AIH) are scarce. A study proposed low ferritin and high IgG as prognostic markers for complete biochemical response (CBR). Aims: We aimed to externally validate the prognostic role of ferritin‐IgG score and its individual components in an independent multicentre AIH cohort. Methods: This multicentre study included 487 patients from the Hannover cohort ( n = 166) and the Spanish ColHai registry ( n = 321). Patients with ferritin < 2.09×ULN received 1 point and those with IgG > 1.89×ULN received 1 point, yielding a score of 0–2. Because baseline characteristics differed between cohorts, the score was additionally evaluated after inverse probability of treatment weighting (IPTW) propensity score. Results: At baseline, Hannover patients were younger ( p = 0.005) and had higher transaminases, bilirubin ( p < 0.001), ferritin ( p = 0.006) and IgG ( p = 0.006). Overall, 79.7% achieved CBR; CBR rates were higher in ColHai at 6 (50.2% vs. 34.6%, p = 0.001) and 12 months (67.6% vs. 51.9%, p = 0.001). The score was associated with response in the Hannover cohort but showed no predictive capacity in ColHai (C‐statistic 0.51 [95% CI 0.45–0.56] at 6 months; 0.51 [0.45–0.57] at 12 months; 0.54 [0.47–0.61] at any time during the follow‐up). After IPTW, the score was not associated with CBR in the ColHai cohort (HR 0.86, 95% CI 0.67–1.10), whereas IgG retained its predictive value, with baseline levels < 1.89×ULN associated with a higher probability of achieving CBR. Conclusions: The ferritin‐IgG score failed external validation in an independent multicentre cohort. Ferritin showed no prognostic value, whereas the predefined IgG threshold retained its ability to predict treatment response.
- 20 January 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (4) , 890-898
An Artificial Intelligence-Guided Strategy to Reduce Poor Bowel Preparation: A Multicenter Randomized Controlled Study
INTRODUCTION: Proper bowel preparation is crucial for increasing the adenoma detection rate. A novel application based on the use of a convolutional neural network can differentiate between adequate and inadequate bowel preparation on the basis of images of rectal effluents taken before the examination. The aim of this study was to evaluate whether a software-driven approach improves colon cleansing quality during colonoscopies compared with standard care. METHODS: A multicenter randomized controlled trial was conducted. Consecutive patients were assigned to a standard-care group or an intervention group. The latter group was trained to use a web application linked to a convolutional neural network, enabling them to send an image of their most recent rectal effluent and receive feedback on the adequacy of their bowel preparation. Patients were instructed to follow the recommendations provided by the platform. RESULTS: Overall, 774 patients were eligible and randomized . The intention-to-treat analysis revealed statistically significant differences in bowel cleansing quality in favor of the intervention group (91% vs 84.2%, OR 1.88, 95% CI [1.21–2.93], P = 0.005). The right and left colon exhibited better cleansing in the intervention group (90.4% vs 84.8%, P = 0.016 and 95.3% vs 91.5%, P = 0.03, respectively). In the per-protocol analysis, bowel cleansing quality was also significantly higher in the intervention group, both overall (93.3% vs 85.6%, OR 2.34 (1.36–4.02), P = 0.002) and by segment. When aiming for excellent bowel preparation (>7), cleansing was significantly better in the intervention group overall and by segment. DISCUSSION: A software application-driven colon cleansing process improves preparation quality in outpatients (NCT05871814).
- 20 January 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (4) , 890-898
An Artificial Intelligence-Guided Strategy to Reduce Poor Bowel Preparation: A Multicenter Randomized Controlled Study
INTRODUCTION: Proper bowel preparation is crucial for increasing the adenoma detection rate. A novel application based on the use of a convolutional neural network can differentiate between adequate and inadequate bowel preparation on the basis of images of rectal effluents taken before the examination. The aim of this study was to evaluate whether a software-driven approach improves colon cleansing quality during colonoscopies compared with standard care. METHODS: A multicenter randomized controlled trial was conducted. Consecutive patients were assigned to a standard-care group or an intervention group. The latter group was trained to use a web application linked to a convolutional neural network, enabling them to send an image of their most recent rectal effluent and receive feedback on the adequacy of their bowel preparation. Patients were instructed to follow the recommendations provided by the platform. RESULTS: Overall, 774 patients were eligible and randomized . The intention-to-treat analysis revealed statistically significant differences in bowel cleansing quality in favor of the intervention group (91% vs 84.2%, OR 1.88, 95% CI [1.21–2.93], P = 0.005). The right and left colon exhibited better cleansing in the intervention group (90.4% vs 84.8%, P = 0.016 and 95.3% vs 91.5%, P = 0.03, respectively). In the per-protocol analysis, bowel cleansing quality was also significantly higher in the intervention group, both overall (93.3% vs 85.6%, OR 2.34 (1.36–4.02), P = 0.002) and by segment. When aiming for excellent bowel preparation (>7), cleansing was significantly better in the intervention group overall and by segment. DISCUSSION: A software application-driven colon cleansing process improves preparation quality in outpatients (NCT05871814).
- Open Access
- 6 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 433
Disease Clearance Reduces the Risk of Adverse Outcomes and Provides Additional Benefit Beyond Individual Clinical, Endoscopic, or Histological Remission in Ulcerative Colitis
Background and Aims: Recent advances in Ulcerative Colitis (UC) treatment have the potential to improve clinical outcomes if inflammation is controlled. The emerging concept of “disease clearance” (DC) aims to achieve combined clinical, endoscopic, and histological remission. However, whether DC is associated with better outcomes remains unclear. This study aimed to evaluate the impact of DC on UC patients. Methods: Consecutive UC patients who underwent colonoscopy and had clinical follow-up of at least 18 months were included between September 2012 and December 2017. Clinical condition (Patient-Reported Outcome, PRO), Mayo endoscopic score (MES), and histopathology (Geboes score, GS) were assessed at baseline and every 6 months. Disease clearance (DC) was defined as simultaneous clinical remission (PRO2 = 0), endoscopic remission (MES = 0), and histological remission (GS ≤ 2). Results: A total of 101 UC patients with a median time since diagnosis of 103 ± 102 months were included. At baseline colonoscopy, 52 patients (51.5%) achieved DC. These subjects had a lower rate of negative outcomes than those without DC (21.2% vs. 59.2%, p < 0.001). Kaplan–Meier curves confirmed a lower risk of clinical relapse in DC patients (log-rank, p = 0.001). Among patients with endoscopic remission, only those with DC had a lower risk of negative outcomes (21.2% vs. 75%, p < 0.01). Achieving DC reduced the risk of flare-ups even in patients with clinical remission or histological remission. Conclusions: Achieving DC in UC patients reduces the risk of negative outcomes during follow-up, supporting its inclusion as a key composite treatment goal in UC management.
- 6 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 433
Open AccessDisease Clearance Reduces the Risk of Adverse Outcomes and Provides Additional Benefit Beyond Individual Clinical, Endoscopic, or Histological Remission in Ulcerative Colitis
Background and Aims: Recent advances in Ulcerative Colitis (UC) treatment have the potential to improve clinical outcomes if inflammation is controlled. The emerging concept of “disease clearance” (DC) aims to achieve combined clinical, endoscopic, and histological remission. However, whether DC is associated with better outcomes remains unclear. This study aimed to evaluate the impact of DC on UC patients. Methods: Consecutive UC patients who underwent colonoscopy and had clinical follow-up of at least 18 months were included between September 2012 and December 2017. Clinical condition (Patient-Reported Outcome, PRO), Mayo endoscopic score (MES), and histopathology (Geboes score, GS) were assessed at baseline and every 6 months. Disease clearance (DC) was defined as simultaneous clinical remission (PRO2 = 0), endoscopic remission (MES = 0), and histological remission (GS ≤ 2). Results: A total of 101 UC patients with a median time since diagnosis of 103 ± 102 months were included. At baseline colonoscopy, 52 patients (51.5%) achieved DC. These subjects had a lower rate of negative outcomes than those without DC (21.2% vs. 59.2%, p < 0.001). Kaplan–Meier curves confirmed a lower risk of clinical relapse in DC patients (log-rank, p = 0.001). Among patients with endoscopic remission, only those with DC had a lower risk of negative outcomes (21.2% vs. 75%, p < 0.01). Achieving DC reduced the risk of flare-ups even in patients with clinical remission or histological remission. Conclusions: Achieving DC in UC patients reduces the risk of negative outcomes during follow-up, supporting its inclusion as a key composite treatment goal in UC management.
- 8 December 2025
- Published by SAGE Publications in Journal of Telemedicine and Telecare
- Vol. 32 (7) , 620-628
Improved appropriateness of electronic consultations in primary care with ongoing liver disease education
Introduction: This study evaluates the short-term impact of two educational strategies on the appropriateness of electronic consultations (e-consults) submitted by primary care physicians (PCPs) to hepatologists for chronic liver disease (CLD) management. We compared a synchronous education program delivered in-person and online by hepatologists with an asynchronous approach based on e-consult feedback. Methods: We conducted a 24-month prospective observational cohort study, analyzing e-consults related to the most prevalent CLD submitted by 326 PCPs to 10 hospital-based specialists in the Department of Gastroenterology and Hepatology. E-consults were categorized into three consecutive 8-month periods based on PCPs’ training exposure: Group I (no training), Group II (synchronous continuing medical education) and Group III (asynchronous education via e-consult feedback). Results: A total of 9934 consecutive e-consults were analyzed, which 663 pertained to CLD cases, submitted by 205 (63%) of 326 eligible PCPs, involving 629 patients (median age: 55 years; 61.8% male). Overall, 68% of e-consults were deemed appropriate, with 58.2% resulting in a specialist care appointment. Appropriateness significantly improved following both synchronous and asynchronous training compared to the pre-training period (75.2% vs. 69.1% vs. 60.1%; p < 0.05). E-consults submitted by trained PCPs were significantly more likely to be appropriate (OR = 2.001; 95% CI: 1.360–2.946; p < 0.001). Conclusion: Both synchronous and asynchronous training significantly improved e-consult appropriateness and reduced unnecessary referrals. Asynchronous education via e-consult feedback emerged as a practical and effective alternative. These findings underscore the importance of educational programs in optimizing e-consult utilization, warranting further research on long-term impacts.
- 8 December 2025
- Published by SAGE Publications in Journal of Telemedicine and Telecare
- Vol. 32 (7) , 620-628
Improved appropriateness of electronic consultations in primary care with ongoing liver disease education
Introduction: This study evaluates the short-term impact of two educational strategies on the appropriateness of electronic consultations (e-consults) submitted by primary care physicians (PCPs) to hepatologists for chronic liver disease (CLD) management. We compared a synchronous education program delivered in-person and online by hepatologists with an asynchronous approach based on e-consult feedback. Methods: We conducted a 24-month prospective observational cohort study, analyzing e-consults related to the most prevalent CLD submitted by 326 PCPs to 10 hospital-based specialists in the Department of Gastroenterology and Hepatology. E-consults were categorized into three consecutive 8-month periods based on PCPs’ training exposure: Group I (no training), Group II (synchronous continuing medical education) and Group III (asynchronous education via e-consult feedback). Results: A total of 9934 consecutive e-consults were analyzed, which 663 pertained to CLD cases, submitted by 205 (63%) of 326 eligible PCPs, involving 629 patients (median age: 55 years; 61.8% male). Overall, 68% of e-consults were deemed appropriate, with 58.2% resulting in a specialist care appointment. Appropriateness significantly improved following both synchronous and asynchronous training compared to the pre-training period (75.2% vs. 69.1% vs. 60.1%; p < 0.05). E-consults submitted by trained PCPs were significantly more likely to be appropriate (OR = 2.001; 95% CI: 1.360–2.946; p < 0.001). Conclusion: Both synchronous and asynchronous training significantly improved e-consult appropriateness and reduced unnecessary referrals. Asynchronous education via e-consult feedback emerged as a practical and effective alternative. These findings underscore the importance of educational programs in optimizing e-consult utilization, warranting further research on long-term impacts.
- Open Access
- 29 August 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (11) , 101562
Isolated IgG elevation in patients with persistently normal transaminases does not affect the outcome of autoimmune hepatitis
- 29 August 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (11) , 101562
Open AccessIsolated IgG elevation in patients with persistently normal transaminases does not affect the outcome of autoimmune hepatitis
- Open Access
- 22 July 2025
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 32 (4) , 1-11
Role of obesity and estrogen deficiency in non‑alcoholic fatty liver disease: Insights from a mouse model
The prevalence of non‑alcoholic fatty liver disease (NAFLD) increases in post‑menopausal women, driven by obesity and metabolic syndrome (MS). However, the pathogenesis of this interaction remains poorly understood. The present study investigated the interplay between obesity, menopause and NAFLD in a C57BL6/J mouse model of diet‑induced obesity. The study included male and female animals, in which a subgroup of females underwent ovariectomy to simulate menopause. Mice were fed a high‑fat diet for 6 months which resulted in them becoming overweight, and developing hyperglycemia and insulin resistance. The present study analyzed liver histology, inflammatory markers and hepatic lipid profiles. All obese animals showed liver steatosis, hepatocyte ballooning and fibrosis. Sex‑related differences were observed, including: i) Obese male mice developed increased expression of inflammatory markers and altered lipid profile; ii) obese female mice exhibited less severe steatosis, hepatic inflammation and lipotoxicity, and iii) ovariectomized obese female mice exhibited exacerbated hepatic lipotoxicity and tissue damage. Ovariectomized obese female mice also had reduced triacylglycerol and cholesteryl ester levels, but increased levels of toxic intermediaries, such as free fatty acids, diacylglycerols and free cholesterol, elevated expression of NF‑κB in the liver and increased levels of serum transaminases, indicating liver damage. These findings suggested that estrogen may protect against NAFLD progression by regulating lipid droplet formation, especially in the context of insulin resistance. More studies in the field are clearly needed to achieve a complete understanding of these pathways, which may serve to improve current therapies.
- 22 July 2025
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 32 (4) , 1-11
Open AccessRole of obesity and estrogen deficiency in non‑alcoholic fatty liver disease: Insights from a mouse model
The prevalence of non‑alcoholic fatty liver disease (NAFLD) increases in post‑menopausal women, driven by obesity and metabolic syndrome (MS). However, the pathogenesis of this interaction remains poorly understood. The present study investigated the interplay between obesity, menopause and NAFLD in a C57BL6/J mouse model of diet‑induced obesity. The study included male and female animals, in which a subgroup of females underwent ovariectomy to simulate menopause. Mice were fed a high‑fat diet for 6 months which resulted in them becoming overweight, and developing hyperglycemia and insulin resistance. The present study analyzed liver histology, inflammatory markers and hepatic lipid profiles. All obese animals showed liver steatosis, hepatocyte ballooning and fibrosis. Sex‑related differences were observed, including: i) Obese male mice developed increased expression of inflammatory markers and altered lipid profile; ii) obese female mice exhibited less severe steatosis, hepatic inflammation and lipotoxicity, and iii) ovariectomized obese female mice exhibited exacerbated hepatic lipotoxicity and tissue damage. Ovariectomized obese female mice also had reduced triacylglycerol and cholesteryl ester levels, but increased levels of toxic intermediaries, such as free fatty acids, diacylglycerols and free cholesterol, elevated expression of NF‑κB in the liver and increased levels of serum transaminases, indicating liver damage. These findings suggested that estrogen may protect against NAFLD progression by regulating lipid droplet formation, especially in the context of insulin resistance. More studies in the field are clearly needed to achieve a complete understanding of these pathways, which may serve to improve current therapies.
- Open Access
- 1 March 2025
- Published by SAGE Publications in Substance Use: Research and Treatment
- Vol. 19
Alcohol Consumption Impacts Liver Fibrosis Progression in Minority of Patients Screened for Hepatitis C at Drug Treatment Centers
Background & Aims: Hepatitis C virus (HCV) infection is a prevalent disease at drug treatment centers (DTC). Alcohol abuse may also contribute to liver fibrosis at DTC, which may affect the prescription of HCV therapy. This study evaluated the risk of alcohol intake and other predictive factors for fibrosis progression. Methods: An on-site dried-blood-spot (DBS) testing program for hepatitis C care at DTC from 2017 to 2019 was used to identify patients with previous HCV-antibody testing and fibrosis score data. Patients were grouped based on RNA status, alcohol intake and advanced liver disease (ALD ⩾ F3). Fibrosis progression was assessed using APRI and FIB-4. Kaplan-Meier and Cox-regression analyses were performed. Results: Positive HCV RNA patients (n = 138) exhibited a higher rate of ALD (11% vs 2.2%, P < .001) and a higher risk of fibrosis progression during follow-up (HR = 3.14, 95% CI: 1.2-8.2) than patients who did not have an infection (n = 230). Overall, 25% (n = 84) reported high-risk alcohol consumption, which was associated with an increased risk of ALD in patients with RNA positivity (HR = 3.2; 95% CI: 1.1-9.1). Alcohol consumption at any dose regardless of HCV infection status was not associated with ALD. Age, high-risk alcohol consumption, and RNA positivity were independent factors for progression to ALD. Conclusions: Patients with active HCV infections at DTC have an increased risk for ALD compared to patients without HCV. High-risk alcohol consumption is present in a minority of patients aggravating fibrosis. These results suggest that HCV treatment should not be delayed at DTC regardless of alcohol consumption.
- 1 March 2025
- Published by SAGE Publications in Substance Use: Research and Treatment
- Vol. 19
Open AccessAlcohol Consumption Impacts Liver Fibrosis Progression in Minority of Patients Screened for Hepatitis C at Drug Treatment Centers
Background & Aims: Hepatitis C virus (HCV) infection is a prevalent disease at drug treatment centers (DTC). Alcohol abuse may also contribute to liver fibrosis at DTC, which may affect the prescription of HCV therapy. This study evaluated the risk of alcohol intake and other predictive factors for fibrosis progression. Methods: An on-site dried-blood-spot (DBS) testing program for hepatitis C care at DTC from 2017 to 2019 was used to identify patients with previous HCV-antibody testing and fibrosis score data. Patients were grouped based on RNA status, alcohol intake and advanced liver disease (ALD ⩾ F3). Fibrosis progression was assessed using APRI and FIB-4. Kaplan-Meier and Cox-regression analyses were performed. Results: Positive HCV RNA patients (n = 138) exhibited a higher rate of ALD (11% vs 2.2%, P < .001) and a higher risk of fibrosis progression during follow-up (HR = 3.14, 95% CI: 1.2-8.2) than patients who did not have an infection (n = 230). Overall, 25% (n = 84) reported high-risk alcohol consumption, which was associated with an increased risk of ALD in patients with RNA positivity (HR = 3.2; 95% CI: 1.1-9.1). Alcohol consumption at any dose regardless of HCV infection status was not associated with ALD. Age, high-risk alcohol consumption, and RNA positivity were independent factors for progression to ALD. Conclusions: Patients with active HCV infections at DTC have an increased risk for ALD compared to patients without HCV. High-risk alcohol consumption is present in a minority of patients aggravating fibrosis. These results suggest that HCV treatment should not be delayed at DTC regardless of alcohol consumption.
- 18 January 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (4) , 931-932
Measured GFR redefined with dried-blood spot: Simplicity with reliability
- 18 January 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (4) , 931-932
Measured GFR redefined with dried-blood spot: Simplicity with reliability
- 24 September 2024
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (2) , 443-449
Low penetrance of frequent ATP7B mutations explains the low prevalence of Wilson disease. Lessons from real-life registries.
- 24 September 2024
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (2) , 443-449
Low penetrance of frequent ATP7B mutations explains the low prevalence of Wilson disease. Lessons from real-life registries.
- Open Access
- 2 May 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (2) , 201-211
Real‐life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Summary: Background: Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct‐acting antivirals (DAAs). Data are limited on the effectiveness of this treatment after the current first‐line therapies. Our aim was to analyse the effectiveness and safety of SOF/VEL/VOX among patients failing sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB). Methods: Retrospective multicentre study (26 Spanish hospitals), including chronic hepatitis C patients unsuccessfully treated with SOF/VEL or GLE/PIB, and retreated with SOF/VEL/VOX ± ribavirin for 12 weeks between December 2017 and December 2022. Results: In total, 142 patients included: 100 (70.4%) had failed SOF/VEL and 42 (29.6%) GLE/PIB. Patients were mainly men (84.5%), White (93.9%), with hepatitis C virus genotype (GT) 3 (49.6%) and 47.2% had liver cirrhosis. Sustained virological response (SVR) was evaluated in 132 patients who completed SOF/VEL/VOX and were followed 12 weeks after end of treatment; 117 (88.6%) achieved SVR. There were no significant differences in SVR rates according to initial DAA treatment (SOF/VEL 87.9% vs. GLE/PIB 90.2%, p = 0.8), cirrhosis (no cirrhosis 90% vs. cirrhosis 87.1%, p = 0.6) or GT3 infection (non‐GT3 91.9% vs. GT3 85.5%, p = 0.3). However, when considering the concurrent presence of SOF/VEL treatment, cirrhosis and GT3 infection, SVR rates dropped to 82.8%. Ribavirin was added in 8 (6%) patients, all achieved SVR. Conclusion: SOF/VEL/VOX is an effective rescue therapy for failures to SOF/VEL or GLE/PIB, with an SVR of 88.6%. Factors previously linked to lower SVR rates, such as GT3 infection, cirrhosis and first‐line therapy with SOF/VEL were not associated with lower SVRs.
- 2 May 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (2) , 201-211
Open AccessReal‐life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Summary: Background: Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct‐acting antivirals (DAAs). Data are limited on the effectiveness of this treatment after the current first‐line therapies. Our aim was to analyse the effectiveness and safety of SOF/VEL/VOX among patients failing sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB). Methods: Retrospective multicentre study (26 Spanish hospitals), including chronic hepatitis C patients unsuccessfully treated with SOF/VEL or GLE/PIB, and retreated with SOF/VEL/VOX ± ribavirin for 12 weeks between December 2017 and December 2022. Results: In total, 142 patients included: 100 (70.4%) had failed SOF/VEL and 42 (29.6%) GLE/PIB. Patients were mainly men (84.5%), White (93.9%), with hepatitis C virus genotype (GT) 3 (49.6%) and 47.2% had liver cirrhosis. Sustained virological response (SVR) was evaluated in 132 patients who completed SOF/VEL/VOX and were followed 12 weeks after end of treatment; 117 (88.6%) achieved SVR. There were no significant differences in SVR rates according to initial DAA treatment (SOF/VEL 87.9% vs. GLE/PIB 90.2%, p = 0.8), cirrhosis (no cirrhosis 90% vs. cirrhosis 87.1%, p = 0.6) or GT3 infection (non‐GT3 91.9% vs. GT3 85.5%, p = 0.3). However, when considering the concurrent presence of SOF/VEL treatment, cirrhosis and GT3 infection, SVR rates dropped to 82.8%. Ribavirin was added in 8 (6%) patients, all achieved SVR. Conclusion: SOF/VEL/VOX is an effective rescue therapy for failures to SOF/VEL or GLE/PIB, with an SVR of 88.6%. Factors previously linked to lower SVR rates, such as GT3 infection, cirrhosis and first‐line therapy with SOF/VEL were not associated with lower SVRs.